Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

about

Towards Stratified Medicine in Plasma Cell Myeloma Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor.Analysis of the interplay between all-trans retinoic acid and histone deacetylase inhibitors in leukemic cells.

P2860

Q28074994-52AA4375-6ADA-4B3F-8C07-CAD6E0DFABA7 Q36298507-BE65B14C-70DD-4B04-9BFD-C30A98D0F406 Q40468248-3E0EB88E-9ACF-40F8-B657-2C5547DBC65A

P2860

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

Item

http://www.wikidata.org/entity/Q38742700

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

@en

type

Item

label

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

@en

prefLabel

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

@en

P1476

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

@en

P2093

Hans C Lee

http://www.w3.org/2001/XMLSchema#string

Jatin J Shah

http://www.w3.org/2001/XMLSchema#string

Tomer M Mark

http://www.w3.org/2001/XMLSchema#string

P2860

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

CD38 and airway hyper-responsiveness: studies on human airway smooth muscle cells and mouse models

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

P2888

s11899-016-0312-7

P304

148-155

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-016-0312-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1046627107

http://www.w3.org/2001/XMLSchema#string

P698

26898556

http://www.w3.org/2001/XMLSchema#string

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

about

P2860

P2860

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698